Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04209153
Recruiting Observational

Direct Transcranial Electrical Stimulation in Tobacco Addiction (tDCS)

NCT04209153 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2021-11-29
Last updated
2025-09-12

Condition(s) studied

Adults (Male and Female Subjects) With Tobacco Dependence

Investigational drug(s) / intervention(s)

Transcranial Direct Current Stimulation

Transcranial Direct Current Stimulation: tDCS sessions (with Direct Transcranial Electrical Stimulation (tDCS) device - Neuroelectrics

Study summary

In summary, there are currently many therapeutic tools for achieving some degree of control or even cessation of tobacco addictive use. No single therapy seems to have proven itself sufficiently effective to be the preferred treatment axis in the management of this addiction. We can also point out that so far the main treatments aimed at reducing or controlling the craving phenomenon are of a pharmacological nature, thus exposing the participants to the side effects inherent to this type of treatment. In this perspective, the establishment of non invasive brain stimulation (TdCS), acting in a targeted manner on craving and whose effects would be mild and transient, appears quite justified, especially in addition to psychotherapy. In the context of the management of addictive pathologies, the choice of smoking dependence seems relevant to us insofar as this addiction represents a major public health problem.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Men and women over the age of 18 * Nicotine dependent subjects according to the Fagerström test (score ≥5) * Subjects consuming daily tobacco. * Subjects understanding and reading French and able to express themselves in this language. * Signed informed consent to participate indicating that the subject has understood the purpose and the procedures required by the study and agrees to participate in the study and to comply with the requirements and limitations of this study * Affiliation to the French social security scheme or beneficiary of such a scheme. * No other method to decrease or stop smoking at the same time as the study. Exclusion Criteria: * Guardianship * Pregnant or lactating woman * Patient under AME * Subject being in the exclusion period of another study or provided for by the "National Volunteer File". * Subjects with intracranial hypertension * Subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator. * Treatment with buproprion or varenicline in progress * Episode or family history of epilepsy, convulsion. * Disease causing damage to the brain (aneurysm, tumor, ...). * Cochlear or ocular implant. * Stimulator or cardiac defibrillator. * Presence of metal in the skull (clip on aneurysm, prosthesis, ...). * Eczema on the scalp.

Primary outcome measure(s)

  • Fagerström score (3 is the highest score and O the lowest one for item 1. A score of 1 or 2 means low dependence (for item 1 only as well as if you use the total score) — 15 days
    average difference in Fagerström score 1 scores that assess craving for tobacco between pre-treatment assessment (J0) and short-term post-treatment evaluations (J15).

Trial sites (1)

FacilityCityRegionStatus
Psychiatrie Adultes Et Addictologie Paris IDF Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases Recruiting
VExUS in Ards Patients and Association with AKI Recruiting
Periodontitis and Inflammation: Study on Biological Samples Recruiting
Kinematic Analysis of Latissimus Dorsi Transfer Results for Shoulder External Rotation Resuscitation Starting soon
Creation of a Biological Collection for Medical Research Purposes for Patients at the Reference Center for Rare Diseases of the Blood Vessels of the Brain and Eye at Lariboisière Hospital Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04209153 on ClinicalTrials.gov ↗ ← All trials in France